On Wednesday, Delphi Automotive PLC (NYSE:DLPH)’s shares declined -0.70% to $87.92.
Delphi Automotive PLC (DLPH) declared that Joseph S. Cantie has joined its board of directors effective June 1.
Cantie is presently the executive vice president and chief financial officer of ZF TRW, a division of ZF Friedrichshafen AG, a global automobile supplier. He served in these roles for TRW Automotive Holdings Corp. since April 2004, and has held various other senior financial administration roles at TRW since joining the company in 1999. Cantie has also held administration roles at LucasVarity and KPMG Peat Marwick.
Cantie is a certified public accountant and has a bachelor’s of science degree from the State University of New York at Buffalo.
Delphi Automotive PLC, together with its auxiliaries, manufacturers vehicle components; and provides electrical and electronic, powertrain, safety, and thermal technology solutions to the automotive and commercial vehicle markets worldwide. The company operates through four segments: Electrical/Electronic Architecture, Powertrain Systems, Electronics and Safety, and Thermal Systems. The Electrical/Electronic Architecture segment provides complete design of the vehicle’s electrical architecture, counting connectors, wiring assemblies and harnesses, electrical centers, and hybrid high voltage and safety distribution systems.
NCR Corporation (NYSE:NCR)’s shares dropped -2.31% to $33.02.
NCR Corporation (NCR) declared that Tesco Stores Ltd. – a partner of U.K.-based Tesco plc – has selected its self-checkout technology for the Malaysian stores. The grocery and general merchandise retailer selected The Tesco store at IOI City Mall in Putrajaya for the pilot deployment. The technology will be installed later at Tesco KSL City in Johor.
The full touch screen NCR self-checkout solution has a user-friendly interface that will guide shoppers through the checkout process. The animated demonstrations on the screen make the technology user-friendly and faster thereby enhancing customers overall shopping experience.
The customers will save a lot of time as this technology will enable them to scan, bag and pay for goods themselves. Per the deal, NCR will provide consulting, training and services to ensure smooth deployment of the technology at Tesco Stores in Malaysia.
At the end of Wednesday’s trade, bluebird bio Inc (NASDAQ:BLUE)‘s shares dipped -2.42% to $170.10.
bluebird bio, Inc. ( BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, recently declared the pricing of an underwritten public offering of 2,941,176 shares of its common stock at a public offering price of $170.00 per share, before underwriting discounts. In addition, bluebird bio has granted the underwriters a 30-day option to purchase from it up to an additional 441,176 shares of common stock.
BofA Merrill Lynch, Morgan Stanley and Cowen and Company are acting as joint book-running managers of the projected offering. SunTrust Robinson Humphrey, Wedbush PacGrow and Roth Capital Partners are acting as co-managers. The offering is predictable to close on or about June 29, 2015, subject to customary closing conditions.
Alcobra Ltd (NASDAQ:ADHD), ended its Wednesday’s trading session with -12.99% loss, and closed at $7.30.
Alcobra Ltd (ADHD) stated that the company’s Phase 2 clinical trial of MDX (Metadoxine Extended Release) for the treatment of FXS did not meet the primary endpoint of change from baseline to week 6 of the inattentive subscale of the Attention Deficit Hyperactivity Disorder Rating Scale (ADHD RS-IV). The difference between treatment groups was not statistically significant. However, MDX did achieve statistical significance, in the Intent-to-Treat (ITT) population, on two secondary endpoints, counting the Vineland Adaptive Behavior Scale (VABS) Daily Living Skills Domain (p=0.044), and the computerized cognitive Test of Attentional Performance for Children (KiTAP) Distractibility subscale (p=0.017). In the study, MDX was generally well tolerated and no safety concerns were identified.
There are no approved medications to treat FXS. MDX has received an Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of FXS. Alcobra plans to talk about these trial results with the FDA before finalizing the design of the next study of MDX in FXS.
Alcobra Ltd., a biopharmaceutical company, focuses on the development and commercialization of oral drug candidates. The company is primarily developing MDX (metadoxine), an onset/extended release formulation of the chemical pyridoxine pyroglutamate, which is in Phase III clinical trial for adults with attention deficit hyperactivity disorder (ADHD); in Phase II clinical trial for pediatric with ADHD; and in Phase II clinical trial in adolescents and adults with Fragile X Syndrome. Alcobra Ltd. was founded in 2008 and is headquartered in Tel Aviv, Israel.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
